AstraZeneca’s Truqap Redeems Itself with Phase III Prostate Cancer Win
AstraZeneca on Monday released high-level data from the Phase III CAPItello-281 trial, demonstrating that a combo regimen based on its AKT inhibitor Truqap (apivasertib) significantly boosts radiographic progression-free survival in patients with one type …